Saturday 17 October 2026 Export OPRX’s income statement to Excel — free account

OptimizeRx Corp.

OPRX Healthcare Health Information Services

OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024. In the quarter to June 2026, revenue fell 29.8%, EPS fell 150.0%, free cash flow grew 89.9% and total debt fell 33.1%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

8.50 0.35 −3.95%

Follow OPRX

Alert me

Market cap: $166.7M
P/E: 35.4×
Fwd P/E: 23.0×
Dividend yield: —
F-score: 8/9
Altman Z: 3.31
Beneish M: −2.77
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 14.78%

Capital & Financial Ratios $m

Market Cap 166.70

Revenue 98.65

Net Income 4.60

Free Cash Flow 18.57

Net Debt (5.09)

Current Ratio 5.58

Debt/Equity 0.15

P/E ratio 35.42

Fwd P/E 23.00

P/S ratio 1.62

P/B ratio 1.22

Past 5Y EPS Growth —

This Y EPS Growth (14.60%)

Next Y EPS Growth 20.63%

Next Y revenue growth (12.06%)

Next 5Y EPS Growth 0.63%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 10.69%

10-year low 10-year high

P/B against its own 10 years 12.42%

10-year low 10-year high

EV/Sales against its own 10 years 12.35%

10-year low 10-year high

EV/FCF against its own 10 years 10.92%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	14	13	23	24
Receivables	37	38	39	27
Inventory	—	—	—	—
Other	—	—	—	—
	54	54	65	54

	2023	2024	2025	Q'26
Payables	2	2	2	1
ST’ Debt	2	2	4	1
Other	—	—	—	—
	18	19	21	10

Compound Annual Growth %

	10y	5y	3y
Sales	31.24%	20.37%	20.56%
Cash Flow	43.23%	0.00%	20.66%
Earnings	0.00%	0.00%	0.00%
Book Value	30.52%	20.75%	0.57%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	20	21	—	—	—
’25	22	29	26	32	109
’24	20	19	21	32	92
’23	13	14	16	28	72
’22	14	14	15	20	62
’21	11	14	16	20	61
’20	8	9	11	16	43

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	9	—	—	—
’25	4	5	3	7	19
’24	2	1	2	0	5
’23	0	(2)	1	(6)	(7)
’22	4	0	3	3	11
’21	2	0	0	(1)	1
’20	(4)	0	0	(3)	(6)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	9	—	—	—
’25	4	5	3	7	19
’24	2	1	2	0	4
’23	0	(3)	1	(5)	(8)
’22	4	0	3	3	10
’21	2	0	0	(1)	0
’20	(4)	0	0	(3)	(6)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.03)	(0.04)	—	—	—
’25	(0.12)	0.08	0.04	0.26	0.27
’24	(0.38)	(0.22)	(0.50)	0.00	(1.10)
’23	(0.37)	(0.24)	(0.17)	(0.23)	(1.91)
’22	(0.21)	(0.21)	(0.19)	(0.02)	(0.64)
’21	(0.04)	0.02	0.00	0.03	0.02
’20	(0.15)	(0.07)	(0.02)	0.08	(0.15)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.95	1.89	3.36	8.63	6.50	31.90	13.33	6.92	3.78	3.99	Analyst estimates 2026–2028 Powerpack
	High	3.72	4.80	18.39	17.24	34.22	99.18	64.22	19.98	16.65	22.25
People
People	Employees	20	24	37	50	57	82	110	117	107	105
	Revenue/emp, $m	0.39	0.51	0.57	0.49	0.76	0.75	0.57	0.61	0.86	1.04
Income, $m
Income, $m	Revenue	8	12	21	25	43	61	62	72	92	109
	Gross margin, %	55.99	49.09	57.56	62.77	55.65	58.14	62.40	59.98	64.45	67.25
	EBT	(2)	(2)	0	(4)	(2)	0	(11)	(25)	(19)	7
	EBT margin, %	(19.86)	(17.35)	1.07	(16.43)	(5.10)	0.62	(18.32)	(35.18)	(21.04)	6.35
	Net income	(2)	(2)	0	(3)	(2)	0	(11)	(18)	(20)	5
	Depreciation	0	0	0	1	2	2	2	3	5	5
Per share, $
Per share, $	Revenue	0.78	1.24	1.96	1.84	2.92	3.56	3.51	4.18	5.04	5.90
	Earnings	(0.15)	(0.21)	0.02	(0.23)	(0.15)	0.02	(0.64)	(1.91)	(1.10)	0.28
	Cash flow	(0.05)	(0.15)	0.07	(0.12)	(0.43)	0.04	0.60	(0.42)	0.27	1.01
	Capex	(0.04)	0.00	(0.01)	(0.12)	(0.01)	(0.03)	(0.01)	(0.05)	(0.02)	0.00
	Free cash flow	(0.08)	(0.15)	0.06	(0.24)	(0.43)	0.01	0.59	(0.47)	0.24	1.01
	Book value	0.79	0.63	1.70	3.35	3.37	7.63	7.09	7.39	6.40	6.91
	Shares, m	10	10	11	13	15	17	18	17	18	19
Valuation, ×
Valuation, ×	P/E	0.00	0.00	529.95	0.00	0.00	2,736.12	0.00	0.00	0.00	45.41
	P/S	3.10	3.74	5.60	5.59	10.67	17.46	4.88	3.36	0.97	2.08
	P/B	3.08	7.29	6.44	3.06	9.25	8.14	2.41	1.90	0.76	1.77
	EV/Sales	2.20	3.32	5.18	4.85	10.44	16.08	3.69	3.67	1.18	2.10
	EV/FCF	(20.88)	(23.34)	156.69	(36.70)	(56.96)	4,106.99	22.15	(33.01)	24.43	12.24
Cash, $m
Cash, $m	Operating cash flow	0	(1)	1	(2)	(6)	1	11	(7)	5	19
	Capex	0	0	0	(2)	0	0	0	(1)	0	0
	Free cash flow	(1)	(2)	1	(3)	(6)	0	10	(8)	4	19
Balance, $m
Balance, $m	Working capital	7	5	12	21	23	106	90	36	35	43
	Total debt	—	—	—	1	0	0	0	36	33	26
	Net debt	(7)	(5)	(9)	(18)	(10)	(84)	(74)	22	19	2
	Shareholders’ equity	8	6	18	45	50	131	126	127	117	128
Returns, %
Returns, %	ROA	(12.94)	(19.81)	1.30	(7.69)	(3.77)	0.38	(8.30)	(11.05)	(11.34)	2.95
	ROIC	(127.11)	(121.25)	1.18	(8.69)	(3.34)	0.48	(14.71)	(11.08)	(6.28)	5.60
	ROE	(18.37)	(29.99)	1.83	(9.93)	(4.65)	0.42	(8.88)	(13.90)	(16.51)	4.18

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CSLT Castlight Health, inc.	$332.4M	— (loss-making)	— (loss-making)	−0.86% (below 0%: shrinking)	n/m	+106.49% (above 0%: growing)	66.20%	(5.42%)	Compare
SPOK Spok Holdings, Inc.	$224.5M	17.7×	16.2×	−1.89% (below 0%: shrinking)	−9.09% (below 0%: shrinking)	−2.00% (below 0%: shrinking)	80.47%	15.50%	Compare
AMWL American Well Corporation	$210.6M	— (loss-making)	— (loss-making)	−26.59% (below 0%: shrinking)	n/m	+266.38% (above 0%: growing)	52.95%	(18.36%)	Compare
SY So-Young International Inc. Sponsored ADR	$198.9M	— (loss-making)	12.8×	+40.84% (above 0%: growing)	n/m	−798.37% (below 0%: shrinking)	44.11%	(8.64%)	Compare
OPRX OptimizeRx Corp.	$166.7M	35.4×	23.0×	−29.77% (below 0%: shrinking)	n/m	+89.86% (above 0%: growing)	76.51%	(0.43%)
DH Definitive Healthcare Corp.	$144.3M	— (loss-making)	— (loss-making)	−9.14% (below 0%: shrinking)	n/m	+21.44% (above 0%: growing)	73.45%	(12.23%)	Compare
HCAT Health Catalyst, Inc.	$135.5M	— (loss-making)	— (loss-making)	−12.68% (below 0%: shrinking)	n/m	+64.26% (above 0%: growing)	49.46%	(51.75%)	Compare
LFMD LifeMD, Inc.	$118.6M	— (loss-making)	— (loss-making)	−3.55% (below 0%: shrinking)	n/m	−247.52% (below 0%: shrinking)	88.82%	(15.08%)	Compare
CCLD CareCloud, Inc.	$82.0M	26.4×	12.5×	+16.45% (above 0%: growing)	n/m	+6.15% (above 0%: growing)	45.24%	5.84%	Compare
Median of peers	$171.6M	—	12.8×	−2.72%	—	+13.80%	59.58%	(10.43%)

All 51 Health Information Services stocks →

OptimizeRx Corp. (OPRX) key facts

Strength: OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024.
OptimizeRx Corp. (OPRX) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, OPRX traded at $8.50, a market capitalization of $166.7 million.
Return on equity was 4.18% and debt-to-equity 0.14.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 3.31 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.